AstraZeneca Imjudo-Imfinzi Combination Approved by FDA to Treat Inoperable Liver Cancer
2022年10月24日 - 3:50PM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said Monday that the U.S. Food and Drug
Administration approved its Imjudo treatment in combination with
Imfinzi for patients with liver cancer when surgery isn't an option
as treatment.
The London-listed pharmaceutical company said the approval was
based on positive results from the Himalaya Phase 3 trial.
Patients in the trial treated with the combination of Imjudo and
Imfinzi experienced a 22% reduction in the risk of death versus
sorafenib, AstraZeneca said. It added that around 31% of patients
were still alive after three years compared with 20% of patients
treated with sorafenib still alive at the same duration of
follow-up.
The Anglo-Swedish pharma giant said regulatory applications for
Imjudo in combination with Imfinzi are currently under review in
Europe, Japan and several other countries.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
October 24, 2022 02:35 ET (06:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
過去 株価チャート
から 3 2024 まで 4 2024
Astrazeneca (LSE:AZN)
過去 株価チャート
から 4 2023 まで 4 2024
